NeuroSense’s PrimeC Has Built a Stronger ALS Data Package, but Financing Is Now the Critical Variable

NeuroSense Therapeutics has spent much of 2026 adding clinical and biomarker evidence around PrimeC, its oral fixed-dose combination of ciprofloxacin and celecoxib for amyotrophic lateral sclerosis.

The next phase is increasingly regulatory rather than purely clinical.

In its September 25 business update, NeuroSense said it is targeting an early December 2026 New Drug Submission, or NDS, in Canada following completion of its Pre-NDS process with Health Canada. The company said the regulator had provided alignment on the planned content and structure of the submission.

The U.S. strategy is less settled. NeuroSense already has FDA clearance to initiate the Phase 3 PARAGON trial, but it is now evaluating a smaller and shorter pivotal design, including an active-comparator study against edaravone. The company also plans to discuss whether its existing dataset could support full approval or an Accelerated Approval pathway. Any revised pivotal design or regulatory pathway still requires FDA agreement.

That distinction matters. A smaller pivotal trial or an accelerated pathway could materially reduce the capital required before a regulatory decision. A conventional global Phase 3 program would leave NeuroSense facing a substantially larger financing requirement.

PARADIGM Produced More Than a Single Positive Signal

PrimeC’s clinical case rests primarily on the Phase 2b PARADIGM study, a multinational randomized, double-blind, placebo-controlled trial involving 68 participants with ALS. Forty-five patients received PrimeC and 23 received placebo during the initial six-month controlled period, followed by a 12-month open-label extension.

The peer-reviewed PARADIGM results were published in JAMA Neurology in March 2026. The study reported a safety profile comparable with placebo and signals across functional decline, ALS-related complications, survival and disease-related biomarkers.

Subsequent analyses strengthened that dataset.

The functional and survival findings are particularly notable for a small Phase 2 program. Longer-term follow-up produced an estimated 36.3-month median survival for participants continuously treated with PrimeC versus 21.4 months for participants initially randomized to placebo and subsequently crossed over to PrimeC. The adjusted analysis corresponded to a 65% reduction in the risk of death, with a hazard ratio of 0.35 and p=0.0037.

Those numbers should nevertheless be interpreted in the context of the trial’s size and design. The survival analysis comes from a relatively small population, and the placebo participants eventually crossed over to active treatment. Confirmation in a larger controlled study remains important.

TDP-43 Adds a Potential Regulatory Dimension

The most interesting addition to the PrimeC dataset arrived in June.

NeuroSense reported that PrimeC produced a statistically significant reduction in neuron-derived extracellular-vesicle-associated TDP-43 relative to placebo at Day 180, with p=0.0421. The difference was maintained through Day 540 among continuously treated participants, where the reported comparison reached p<0.001.

TDP-43 pathology is found in more than 97% of ALS cases, making the biomarker biologically relevant to a broad ALS population rather than a narrow genetic subtype.

The regulatory question is more difficult.

A statistically significant change in a disease-associated biomarker does not automatically make that biomarker an acceptable surrogate endpoint for Accelerated Approval. FDA would need to determine that the endpoint is reasonably likely to predict clinical benefit in the context of PrimeC’s development program.

There is, however, an important ALS precedent.

In 2023, FDA granted Accelerated Approval to Qalsody, or tofersen, for SOD1-associated ALS based on a reduction in plasma neurofilament light, or NfL. FDA determined that the biomarker reduction was reasonably likely to predict clinical benefit, while requiring confirmatory evidence.

That does not mean TDP-43 will receive the same regulatory treatment. Qalsody targets a specific genetic form of ALS, its biomarker and mechanism are different, and each accelerated-approval decision is product-specific.

But it shows that FDA has already used a biomarker-based accelerated pathway in ALS.

For NeuroSense, the value of the TDP-43 result therefore goes beyond scientific validation. If FDA ultimately accepts a biomarker-supported regulatory strategy alongside the functional and survival data, the amount of additional clinical work required before a potential filing could change substantially.

The Existing Treatment Benchmark Remains Modest

ALS continues to have a large therapeutic need.

FDA describes the disease as progressive and generally fatal, with death often occurring within three to five years after symptoms appear.

The efficacy benchmark established by older ALS therapies is also relatively modest.

FDA’s review of edaravone notes that the pivotal study produced a 33% reduction in the rate of functional decline over 24 weeks, while historical analyses of riluzole indicate a survival extension of approximately three months. FDA also noted that no survival benefit had been demonstrated for edaravone.

PrimeC’s reported PARADIGM results therefore compare favorably at a headline level, particularly the functional and survival signals.

That comparison has limits. PARADIGM was much smaller, patient populations and trial designs differ, and cross-trial comparisons cannot establish relative efficacy. A larger confirmatory study would provide a much stronger basis for assessing whether PrimeC’s apparent treatment effect persists.

The Balance Sheet Is the Immediate Constraint

The clinical story is stronger than NeuroSense’s financial position.

The company reported just $231,000 of cash and cash equivalents at June 30, 2026, against approximately $3.0 million of current liabilities. Total current assets were $844,000.

That equates to a current-asset-to-current-liability ratio of approximately 0.28x.

Operating expenses declined during the first half, but the absolute cash requirement remains significant for a company preparing late-stage clinical and regulatory work.

NeuroSense generated approximately $2.07 million from share issuance during the first half, yet ended June with only $0.23 million of cash.

The company explicitly says it is pursuing financing opportunities, including potential non-dilutive funding, as well as partnerships and other strategic transactions.

This makes financing a near-term part of the investment thesis rather than a secondary consideration.

The Market Is Assigning Limited Value to the Clinical Optionality

NeuroSense completed a 1-for-20 reverse share split effective September 14, reducing its outstanding ordinary shares from approximately 37.94 million to about 1.90 million.

The shares closed at approximately $6.95 on September 25, giving the company an equity value of roughly $13 million based on available post-split share data.

For a company with an FDA-cleared Phase 3 program, peer-reviewed Phase 2b data and a potential Canadian regulatory submission approaching, that valuation is low in absolute terms.

But the discount is understandable.

The market is effectively balancing two very different sets of facts:

• Randomized Phase 2b evidence
• Peer-reviewed JAMA Neurology publication
• Statistically significant functional signals
• Longer-term survival signal
• TDP-43 biomarker result
• FDA clearance for PARAGON
• Planned Canadian NDS
• Potential discussion of Accelerated Approval

• $0.23 million of reported cash at June 30
• Negative working capital
• Additional capital required
• Potential shareholder dilution
• Small Phase 2b sample
• Crossover complications in longer-term analyses
• No FDA agreement yet on a reduced pivotal program
• No assurance that TDP-43 will qualify as an acceptable surrogate endpoint

That combination explains why a seemingly advanced clinical asset can coexist with a micro-cap valuation.

The Regulatory Path Could Have an Outsized Effect on Equity Value

For many development-stage biotechnology companies, the next clinical result is the primary catalyst.

NeuroSense is somewhat different.

Its most important near-term variable may be how much additional evidence regulators require, rather than whether the existing Phase 2 dataset produces another positive analysis.

A full, large Phase 3 program would increase the financing burden substantially and could make dilution the dominant equity consideration.

A smaller and shorter pivotal program would improve the economics.

A credible accelerated pathway based on the totality of the clinical, survival and biomarker evidence could change them further.

The planned Canadian filing creates a separate regulatory route. A December submission would move PrimeC into formal review without waiting for completion of a new U.S. pivotal study, although submission does not imply acceptance or approval.

The Investor Takeaway

NeuroSense presents an unusual small-cap biotechnology setup.

The company has produced a broader clinical dataset than its roughly $13 million equity value might initially suggest. PrimeC has generated functional, survival and biomarker signals in ALS, the core Phase 2b results have undergone peer review, and the program has progressed to the point where regulatory strategy is becoming the central issue.

But the balance sheet leaves little room for delay.

With only $0.23 million of cash reported at June 30, NeuroSense will need additional capital, non-dilutive funding, a partnership, a strategic transaction, or some combination of these to advance PrimeC.

That creates a clear asymmetry.

If regulators permit a materially more capital-efficient development path, the economic value of the existing clinical dataset could increase substantially relative to the company’s current valuation.

If a conventional large Phase 3 program remains necessary, financing requirements and dilution could absorb a significant portion of that potential value.

For investors, the next important question is therefore not simply whether PrimeC’s Phase 2 data look promising. It is what regulators require NeuroSense to do next, and how the company finances it.